Gilead Sciences, Inc. (ETR:GIS)
Germany
· Delayed Price · Currency is EUR | Market Cap | 128.24B |
| Revenue (ttm) | 27.77B |
| Net Income (ttm) | 463.63M |
| Shares Out | n/a |
| EPS (ttm) | 0.37 |
| PE Ratio | 276.61 |
| Forward PE | n/a |
| Dividend | 2.87 (2.82%) |
| Ex-Dividend Date | Mar 14, 2025 |
| Volume | 631 |
| Average Volume | 2,485 |
| Open | 103.52 |
| Previous Close | 102.80 |
| Day's Range | 103.30 - 103.52 |
| 52-Week Range | 57.29 - 111.84 |
| Beta | 0.24 |
| RSI | 54.37 |
| Earnings Date | Apr 24, 2025 |
About Gilead Sciences
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p... [Read more]
Financial Performance
In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.
Financial numbers in USD Financial StatementsNews
Trump Weighs Tariffs on Ireland's Pharma Industry. How to Play the Sector.
Biopharmaceutical stocks are having their time in the spotlight thanks to President Donald Trump, who vowed to take aim at Ireland's status as a pharma hub with new tariffs. Analysts at Jefferies JEF-...
Gilead Sciences: Using Lessons From the HIV Epidemic To Help Reduce Stigma Around Lung Cancer
NORTHAMPTON, MA / ACCESS Newswire / March 25, 2025 / HIV infection and lung cancer have little in common from a disease perspective, but the stigma that surrounds both can negatively impact patients a...
Gilead: Expansion Of Livdelzi For PBC Continues With European Marketing Approval
Gilead Sciences sees strong growth in HIV & oncology with BIKTARVY & TRODELVY. Learn about upcoming drugs & market potential for 2024.
Stocks making the biggest moves midday: Boeing, Nvidia, Autodesk, Gilead Sciences and more
These are the stocks posting the largest moves in midday trading.
Gilead Dives As HHS Reportedly Mulls Cutting HIV Prevention Funding
Gilead stock tumbled Wednesday on reports HHS could slash federal funding for HIV prevention, a staple in Gilead Sciences' topline.
Gilead Stock Falls on Report Trump Administration Wants to Cut HIV-Prevention Funding
Gilead Sciences is the maker of Biktarvy and Descovy, two drugs used to treat the virus.
Stocks making the biggest moves premarket: General Mills, Gilead Sciences, Tesla and more
These are the stocks posting the largest moves in premarket trading.
Trump Administration Weighs Deep Cuts To Domestic HIV Prevention Programs, Gilead Stock Slides
Gilead Sciences Inc (NASDAQ: GILD) stock is trading lower during the premarket trading session on Wednesday. According to a Tuesday report in the Wall Street Journal, the Health and Human Services De...
Stocks to Watch Wednesday: Tesla, Nvidia, Gilead, GSK
Biggest stock movers Wednesday: STNE, GILD, and more
Gilead, GSK could be impacted by potential HHS HIV prevention cuts
Unpacking the Latest Options Trading Trends in Gilead Sciences
Deep-pocketed investors have adopted a bullish approach towards Gilead Sciences (NASDAQ: GILD), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...
Gilead Sciences Ranked in Top Five Most JUST List for Biopharma Companies
NORTHAMPTON, MA / ACCESS Newswire / March 18, 2025 / We're proud to once again be ranked in the top five of Americas Most Just companies in biopharma. The honor reflects our ongoing commitment to oper...
Gilead: Growth Constraints Lead To Rating Downgrade Following 50% Rally
Gilead's dominance in HIV faces Medicare pricing challenges, limiting growth.
Calls of the Day: Shake Shack, Starbucks, 3M, Gilead Sciences, Eli Lilly
The Investment Committee debate the latest Calls of the Day.
Calls of the Day: Shake Shack, Starbucks, 3M, Gilead Sciences, Eli Lilly
The Investment Committee debate the latest Calls of the Day.
Gilead Sciences - Women's History Month Celebrated With Its Team
NORTHAMPTON, MA / ACCESS Newswire / March 14, 2025 / In recognition of Women's History Month, our Identity + Innovation spotlight features Devi SenGupta. Hear how Devi's background has shaped her appr...
We asked AI: The Handmaid’s Tale season 6 release date, cast and plot details
The dystopian world of Gilead is set to make its final bow as “The Handmaid’s Tale” returns for its sixth and concluding season. Fans worldwide are eager to uncover the fate of June Osborne and her al...
Is Gilead Sciences Gaining or Losing Market Support?
Gilead Sciences's (NYSE: GILD) short percent of float has risen 6.47% since its last report. The company recently reported that it has 22.58 million shares sold short , which is 1.81% of all regular ...
Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and pipeline at the Conference o...
Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment port...
Gilead posts early Phase 1 data for once-yearly HIV PrEP therapy
Gilead Sciences, Inc. (GILD) Leerink Partners Global Healthcare Conference - (Transcript)
Stocks beating the stock market's recent Trump slump have this in common
This year's top performer among the S&P 500 has been CVS Health's stock, which had a bad 2024 and is cheap by a key valuation measure.